Artesunate-and amodiaquine-associated extrapyramidal reactions: A series of 49 cases in vigibase™

Drug Safety

Volumn 35, Issue 8, 2012, Pages 667-675

  McEwen, John ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

Author keywords

Adverse drug reactions; Amodiaquine; Artesunate; Dystonia

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTESUNATE; BENZATROPINE; CHLORAMPHENICOL; CHLORPHENIRAMINE MALEATE; DIAZEPAM; DICLOFENAC; DIHYDROARTEMISININ; HYDROCORTISONE; METHOPROMAZINE; PARACETAMOL; PROMETHAZINE; SULFAMETHOXAZOLE; TRIHEXYPHENIDYL; TRIMETHOPRIM; UNCLASSIFIED DRUG; WINTHROP;

ADULT; ADVERSE OUTCOME; ARTICLE; CASE STUDY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALARIA FALCIPARUM; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AFRICA; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; BASAL GANGLIA DISEASES; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALE; YOUNG ADULT;

EID: 84863818245     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11599860-000000000-00000     Document Type: Article

References (24)

1. Akindele MO, Odejide AO. Amodiaquine-induced involuntary movements. BMJ 1976; 2: 14-5
2. Adonis-Koffy L, Daubrey T, Kouadio A, et al. Effets neurologiques indésirables méconnus de l'amodiaquine. Bull Soc Pathol Exot 2003; 96: 302-7
3. Kamagaté M, Dié-Kacou H, Balayssac E, et al. Oro-facial dyskinesias and amodiaquine [letter]. Therapie 2004; 59: 565-6
4. Akpalu AK, Nyame PK, Dodoo ANO. Amodiaquineinduced dystonic reactions: case reports and implications for policy change in Ghana. Int J Risk Safety Medicine 2005; 17: 1-4 (Pubitemid 41202226)
5. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva:World Health Organization, 2010: ix
6. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 2008; 42: 409-19
7. Introductory guide to standardised MedDRA queries (SMQs). Version 14.0. Chantilly (VA). Maintenance and Support Services Organization, 2011 Mar
8. Dodoo ANO. Global support for regional problems? Uppsala Reports 2008; 43: 13 [online]. Available from URL: http://www.who-umc.org/graphics/24357.pdf [Accessed 2010 Jun 16]
9. Fajolu IB, Lesi FEA. Drug-induced acute dystonia in a 7 year old child following the use of artesunate-amodiaquine: a case report. Int J Risk Saf Med 2010; 22: 111-4
10. Ball R. Drug-induced akathisia: a review. J R Soc Med 1985; 78: 748-52 (Pubitemid 16248377)
11. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ 1985; 291: 930-2 (Pubitemid 16236563)
12. Parikh S, Ouedraogo JB, Goldstein JA, et al. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007; 82: 197-203 (Pubitemid 47075331)
13. Gil JP. Amodiaquine pharmacogenetics. Pharmacogenomics 2008; 9: 1385-90
14. World Health Organization. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2006: 89
15. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization, 2010: 75
16. Taylor WRJ, Terlouw DJ, Olliaro PL, et al. Use of weightfor-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Organ 2006; 84: 956-64 (Pubitemid 44901752)
17. Staedke SG, Jagannathan P, Yeka A, et al. Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J 2008; 7: 107-17
18. Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009; (3): CD007483
19. Summary of product characteristics: artesunate/amodiaquine tablets (Sanofi-Aventis), MA056, MA057, MA058. In: WHOPAR part 4. 09/2010, version 1.1: 6-7 [online]. Available from URL: http://apps.who.int/prequal/WHOPAR/ WHOPARPRODUCTS/MA058part4v1.pdf [Accessed 2011 May 30]
20. Sanofi-Aventis. Application for inclusion of artesunate/amodiaquine fixed dose combination tablets in the WHO model lists of essential medicines. June 2009, updated Sept 2010 [online]. Available from URL: http://www.who.int/ selection-medicines/committees/expert/18/applications/Sanofi-application.pdf [Accessed 2011 Mar 28]
21. Summary of product characteristics: amodiaquine (150 mg base) tablets (Guilin), MA045. In: WHOPAR part 4. 06/2011 [online]. Available from URL: http://apps.who.int/prequal/WHOPAR/WHOPARPRODUCTS/MA045part4v2. pdf [Accessed 2011 Sept 15]
22. Caveat document: accompanying statement to data released from theWHOCollaborating Centre.WHOCollaborating Centre for International Drug Monitoring [online]. Available from URL: http://www.who-umc.org/graphics/25027. pdf [Accessed 2011 Jun 19]
23. WHO briefing on malaria treatment guidelines and artemisinin monotherapies. Geneva: World Health Organization, 2006: 17 [online]. Available from URL: http://www.who. int/malaria/publications/atoz/meeting-briefing19april. pdf [Accessed 2011 May 19]
24. Talisuna AO, Staedke SG, D'Alessandro U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J 2006; 5: 50-8